Search This Blog

Tuesday, November 6, 2018

Two years in, Trump holds stock market bragging rights


U.S. President Donald Trump has taken credit for the stock market’s gains during his nearly two years in the White House, and those claims are reasonable given the impact of tax cuts and pro-business policies on investor sentiment.
The S&P 500 has risen 28 percent since Trump’s election in November 2016 to the eve of congressional midterm elections on Tuesday. This surpasses the market’s performance over the same time frame under any other president in the past 64 years. Under President Dwight Eisenhower, the S&P 500 rose 29 percent from his election in November 1952 through November 1954.
Sweeping corporate tax cuts, an initiative driven by Trump, supercharged U.S. companies’ earnings and helped lift the cash-rich technology sector. The Republican party last year passed the biggest overhaul of the U.S. tax code in over 30 years, boosting U.S. corporate earnings.
Still, other sectors that could have been expected to benefit strongly from a Trump presidency have lagged. Indeed, the individual stocks that have gained and lost the most during his reign have little discernable link to Trump’s presidency.

How the market shakes out in the final two years of Trump’s presidency will probably be influenced by Tuesday’s elections. Analysts expect pressure on stocks if Democrats gain control of the House of Representatives and a sharper downward reaction if they sweep the House and Senate.
On the contrary, if Republicans hold their ground, stocks could gain further, with hopes of more tax reform ahead.
The following graphics show how the Trump presidency has played out on a macro and micro level:
Reuters Graphic
Trump’s strong stock market record has been maintained even after a recent pullback on Wall Street as worries about trade battles, inflation and rising interest rates have increased caution among investors. Starting in 2010 under President Barack Obama as the world recovered from the financial crisis, the S&P 500 has enjoyed its longest bull market in history.
With more than half of Trump’s presidency still to come, how the market will perform over his whole term is unknown. Democratic President Bill Clinton saw the S&P 500 triple during his two terms in the White House.
Average S&P 500 company earnings per share are on track to rise 24 percent this year, the strongest annual gain in eight years, according to IBES data from Refinitiv.
Investor confidence stemming from the tax cuts and Trump’s other business-friendly policies so far have more than made up for ongoing worries on Wall Street that his trade conflict with China is hurting the U.S. economy, and that it could become worse.
The tax cuts also led Apple (AAPL.O) and other multinationals in the technology sector to repatriate billions of dollars in profits held overseas, some of which went toward buying back stock and sending Wall Street higher.
The S&P 500 information technology index .SPLRCT has gained 51 percent since Trump’s election. Financials .SPSY, which benefited from Trump’s deregulation of the banking industry, have climbed 34 percent since Nov 8, 2016.
Reuters Graphic
Still, some companies that had been expected to boom under Trump have fared poorly. The S&P 500 energy index .SPNY is flat since Trump’s election, even though crude prices LCOc1 rose over 50 percent during that time and despite Trump putting the brakes on Obama-era policies aimed at reducing the country’s reliance on oil.
Reuters Graphic
Semiconductors have fared better than any other industry group, even though they are highly exposed to China and could become casualties in Trump’s trade war with Beijing.
Stocks rally peters out as trade, Fed worries dominate
Along with telecommunications, food and tobacco companies, automakers on average have fared worst among 27 industry group’s since Trump’s election. General Motors Co (GM.N) and Ford Motor Co (F.N) have been wrestling for years with tepid global demand, with recent signs of a deep slowdown in China.
Industry groups are more detailed categories than the 11 sectors widely tracked on the stock market.
Reuters Graphic
Interest rates, economic growth, company earnings and inflation are widely viewed as strong influences on stock prices, making who holds power in Washington just one of many factors affecting investor sentiment.
Abiomed Inc (ABMD.O), the S&P 500’s top performer since Trump’s election, has jumped over 260 percent, helped in part by the success of its Impella heart pumps.
General Electric’s (GE.N) 68 percent loss makes it the S&P 500’s worst performer since Trump was elected. The former industrial powerhouse has foundered in several key markets in recent years and is aggressively cutting costs and selling businesses.

National Health Investors sees adjusted FFO $5.01-$5.03, consensus $5.51


Sees FY18 net income $3.73-$3.75 per diluted common share, Normalized FFO $5.47-$5.51. The Company’s guidance range reflects the existence of volatile economic conditions, but does not assume any material deterioration in tenant credit quality and/or performance of its portfolio. The Company has announced or completed $159.0M of new investments since January 1.

Aveo Pharmaceuticals price target raised to $9 from $6.50 at H.C. Wainwright


H.C. Wainwright analyst Swayampakula Ramakanth raised his price target for Aveo Pharmaceuticals to $9 saying the company announced positive topline results from the Phase 3 TIVO-3 study investigating the use of tivozanib for the treatment of refractory renal cell carcinoma. The analyst views the results as “very promising” and believes tivozanib still has “ample opportunity” to show a superior overall survival benefit. He believes the drug is on track for approval in 2020 and keeps a Buy rating on Aveo Pharmaceuticals.

BioCryst reports Q3 EPS (28c), consensus (25c)


Reports Q3 revenue $1.45M, consensus $3.77M. Based upon development plans, merger-related incurred costs from the terminated merger agreement with Idera and awarded government contracts, BioCryst continues to expect its previously issued 2018 financial outlook to be appropriate, with net operating cash use to be in the range of $85 to $105 million, and its 2018 operating expenses to be in the range of $90 to $110 million. The company’s operating expense range excludes equity-based compensation expense due to the difficulty in reliably projecting this expense, as it is impacted by the volatility and price of the company’s stock, as well as by the vesting of the company’s outstanding performance-based stock options.

Neuronetics raises FY18 revenue view to $51M-$52.5M from $50M-$51.5M


Consensus $50.95M.

Alkermes price target lowered to $41 from $46 at Cantor Fitzgerald


Cantor Fitzgerald analyst William Tanner lowered his price target for Alkermes to $41 from $46 and reiterates a Neutral rating on the shares. The FDA advisory panel view of the ALKS 5461 NDA is a “major setback” not only for the drug but also to the ability of Alkermes to convince investors that the company can develop proprietary therapies of meaningful commercial potential, Tanner tells investors in a research note. He now believes the upcoming ALKS-3831 Enlighten-2 data release “looms larger” after the ALKS 5461 panel decision.
https://thefly.com/landingPageNews.php?id=2818231

Spark Therapeutics reports Q3 EPS ($1.26), consensus (98c)


Reports Q3 revenue $10.7M, consensus $26.22M.
https://thefly.com/landingPageNews.php?id=2818259